Loading...
Market
Will Viridian Therapeutics submit a BLA for VRDN-001 in 2025?
2
Viridian Therapeutics•Veligrotug•Clinical Activity Score•Viridian•Biologics License Application•Amgen
Resolution / Starting Odds
Yes • 50%
No • 50%
Viridian Therapeutics' official announcements or FDA submission records
Story
Viridian Therapeutics Announces Positive Results from Phase 3 THRIVE Trial for TED with VRDN-001 Veligrotug
Sep 10, 2024, 11:06 AM
Viridian Therapeutics announced positive topline results from its Phase 3 THRIVE clinical trial of Veligrotug (VRDN-001), an experimental treatment for thyroid eye disease (TED). The results showed significant improvement in reducing eye bulging and achieving primary goals. Key findings include a 70% proptosis responder rate, 54% complete resolution of diplopia, and 64% reduction of Clinical Activity Score to 0 or 1. The treatment was well-tolerated with no treatment-related serious adverse events. Viridian plans to submit a Biologics License Application (BLA) in 2025. The results compared favorably to a similar drug already approved and sold by Amgen. A webcast to discuss the results is scheduled for September 10, 2024, at 8:00am ET.
View original story
Similar markets
Approved without conditions • 25%
Approved with conditions • 25%
Rejected • 25%
No decision by deadline • 25%
Yes • 50%
No • 50%
Approved by FDA • 25%
Approved by EMA • 25%
Approved by both FDA and EMA • 25%
Not approved • 25%
Approved at 20 mg dose • 25%
Approved at higher dose • 25%
Approved at multiple doses • 25%
Not approved • 25%
